Evidence‑Based Recommendations for Herpes Zoster Management

Intravenous Antiviral Therapy for Severe Disease

Hospitalized patients with disseminated infection, encephalitis, pneumonitis, hepatitis, or other life‑threatening complications should receive intravenous acyclovir at 5–10 mg/kg every 8 hours for 5–7 days. This regimen is recommended by the CDC (MMWR) 1.

Immunocompromised individuals require higher oral acyclovir dosing (400 mg 3–5 times daily) and continuation of therapy until complete clinical resolution, as advised by CDC (MMWR) 1.
If lesions persist despite appropriate acyclovir therapy, acyclovir‑resistant VZV should be presumed; treatment of proven or suspected resistance includes intravenous foscarnet 40 mg/kg every 8 hours until resolution or topical cidofovir 1 % gel once daily for 5 days (CDC, MMWR) 1.
All acyclovir‑resistant strains are also resistant to valacyclovir and most to famciclovir (CDC, MMWR) 1.
Close monitoring for treatment failure and signs of dissemination is essential in this population (CDC, MMWR) 1.

Oral acyclovir is considered safe for treating herpes zoster during pregnancy, with registry data showing no increased risk of major birth defects compared with the general population (CDC, MMWR) 1.
For life‑threatening maternal infections (e.g., disseminated disease, encephalitis, pneumonitis, hepatitis), intravenous acyclovir is indicated (CDC, MMWR) 1.

Topical acyclovir is substantially less effective than systemic therapy and should be avoided because it cannot reach the dorsal root ganglia where viral reactivation occurs (CDC, MMWR) [2][3].

The recombinant zoster vaccine (RZV/Shingrix) is preferred over the live‑attenuated vaccine for adults ≥ 50 years due to superior efficacy and longer durability of protection (Journal of Microbiology, Immunology and Infection) 4.
RZV is also safe for immunocompromised individuals, whereas the live‑attenuated vaccine is contraindicated in this group (Journal of Microbiology, Immunology and Infection) 4.

Oral acyclovir 800 mg taken five times daily for 7–10 days is recommended as a first‑line systemic antiviral for herpes zoster. (CDC MMWR Recommendations) 5

Antiviral therapy should be started as early as possible, ideally within 72 hours of rash onset, because peak VZV titers occur within the first 24 hours after lesion appearance and early treatment yields the greatest clinical benefit. (Journal of Clinical Virology) 6

Intravenous acyclovir 5–10 mg/kg every 8 hours for 5–7 days is indicated for hospitalized patients with disseminated infection, encephalitis, pneumonitis, hepatitis, or acyclovir‑resistant VZV. (CDC MMWR Recommendations) 5, 7

Immunocompromised individuals may require higher oral acyclovir doses (400 mg three to five times daily) and prolonged treatment courses to achieve adequate viral suppression. (CDC MMWR Recommendations) 7
For acyclovir‑resistant VZV in immunocompromised patients, foscarnet 40 mg/kg IV every 8 hours or topical cidofovir 1 % gel once daily for 5 days is recommended. (CDC MMWR Recommendations) 7
Oral acyclovir is considered safe for treating a first clinical episode of herpes zoster during pregnancy, with registry data showing no increased risk of major birth defects. (CDC MMWR Recommendations) 7

Topical acyclovir is substantially less effective than systemic therapy and should be avoided for both treatment and prophylaxis of herpes zoster, as it cannot reach the dorsal root ganglia where viral reactivation occurs. (CDC MMWR Recommendations) 5, 8, 9

The recombinant zoster vaccine (RZV/Shingrix) is preferred over the live‑attenuated vaccine for adults ≥ 50 years, owing to superior efficacy and longer durability of protection. (Journal of Microbiology, Immunology and Infection) 10